Key Takeaways
- UnitedHealth shares climbed 1.5% Monday, reaching an intraday high of $283.30 and settling at $281.46.
- CMS announced a final Medicare Advantage payment rate increase of 2.48% for 2027, dramatically higher than the 0.09% preliminary figure released in January.
- The rate adjustment will deliver insurers an additional $13 billion in federal payments during the next year.
- Raymond James elevated UNH to “outperform” from “market perform” with a $330 target ahead of first-quarter results scheduled for April 21.
- In premarket action, Humana surged 11% on the Medicare announcement while UNH and CVS Health each advanced over 6%.
UnitedHealth shares began Monday’s session at $277.26, climbed to $283.30 during trading, and ended the day at $281.46 — representing a 1.5% increase.
UnitedHealth Group Incorporated, UNH
The healthcare giant’s stock has declined approximately 22% during the past six months, trading beneath both its 50-day moving average at $283.03 and its 200-day moving average at $319.62. Wall Street analysts maintain a consensus price target of $363.38.
Following Monday’s market close, the Centers for Medicare and Medicaid Services (CMS) unveiled its final payment rate structure for Medicare Advantage plans in 2027. The announced 2.48% average increase marked a substantial improvement over January’s preliminary 0.09% proposal, which had created significant concern throughout the healthcare insurance sector.
When the initial January figure was disclosed, both UNH and Humana experienced share price declines. Market participants had been anxiously awaiting the final determination to assess whether improvements would materialize.
The enhanced rate structure will generate $13 billion in incremental insurer payments throughout the coming year. Following the announcement, UNH and CVS Health, Aetna’s parent company, jumped more than 6% in premarket activity. Humana shares soared 11%.
Why Medicare Advantage Matters for Health Insurers
Medicare Advantage serves as the privately administered option to traditional Medicare, currently providing coverage to approximately 35 million beneficiaries this year, per health research organization KFF. Program enrollment has expanded consistently and now surpasses traditional Medicare participation.
For companies like UnitedHealth, this program represents a critical revenue source. An almost flat rate adjustment — against a backdrop of medical costs rising between 7% and 9% annually — would have effectively functioned as a reduction, according to the Better Medicare Alliance.
Mizuho analyst Jared Holz characterized the 2.48% final rate as “certainly better than the government’s initial rate decision,” noting that it establishes a foundation for margin growth in the coming year if insurers continue optimizing benefits and controlling expenses.
TD Cowen analyst Ryan Langston had anticipated a more conservative increase between 1% and 1.5%, making the final announcement exceed certain projections.
Bipartisan political dynamics had complicated rate forecasts. Legislators from both parties have expressed concerns regarding insurers receiving elevated payments through diagnosis coding practices — commonly referred to as risk adjustment. The Biden administration initiated tightening of these regulations, and the Trump administration’s January preliminary proposal indicated ongoing regulatory scrutiny.
First Quarter Earnings Expected April 21
Raymond James upgraded its UNH rating from “market perform” to “outperform” on April 1, establishing a $330 price objective. The investment firm pointed to opportunities for management to demonstrate operational stabilization ahead of quarterly results.
Barclays maintains an “overweight” rating with a $327 target price. Mizuho and Leerink Partners similarly rate the stock “outperform,” with price objectives of $350 and $345 respectively.
Among 28 analysts tracking UnitedHealth, 18 assign Buy ratings, seven recommend Hold, and two rate it Sell. MarketBeat’s consensus rating is Moderate Buy.
First-quarter financial results are scheduled for release on April 21. During the fourth quarter, UNH reported earnings per share of $2.11, surpassing the consensus forecast of $2.09. Revenue totaled $113.73 billion, reflecting 12.3% year-over-year growth. Management has provided fiscal 2026 EPS guidance of $17.75.
UnitedHealth distributes a quarterly dividend of $2.21 per share, yielding 3.1% annually based on current trading levels.
Institutional investors hold 87.86% of outstanding shares, with recent stake increases from Norges Bank, Berkshire Hathaway, and T. Rowe Price.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
